NCT00847145已完成3 期
A Phase 3, Open Label, Multi-Center, Extension Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster at 12 Months of Age or as a Two-dose Catch-up to Healthy Toddlers Who Participated in Study V72P13
Novartis Vaccines117 个研究点 分布在 4 个国家目标入组 2,249 人开始时间: 2009年2月最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 2,249
- 试验地点
- 117
- 主要终点
- Percentages of Subjects With Serum Bactericidal Antibody Titers ≥1:5 After Receiving the Booster Dose of rMenB+OMV NZ Vaccination
研究概览
简要总结
The proposed study is an Extension Study of V72P13 to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered as a Booster at 12 Months of Age or as a Two-dose Catch-up to Healthy Toddlers
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 365 Days 至 394 Days（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy 12-month-old toddlers (0/ +29 days) who completed Study V72P13
排除标准
- •Previous ascertained or suspected disease caused by N. meningitidis;
- •History of severe allergic reaction after previous vaccinations or hypersensitivity to any vaccine component;
- •Any serious chronic or progressive disease
- •Known or suspected impairment/ alteration of the immune system,
- •Receipt of, or intent to immunize with another vaccine, within 30 days prior to enrollment.
结局指标
主要结局
Percentages of Subjects With Serum Bactericidal Antibody Titers ≥1:5 After Receiving the Booster Dose of rMenB+OMV NZ Vaccination
时间窗: one month after the booster (fourth) dose
Immunogenicity was assessed in terms of the percentage of subjects as measured by serum bactericidal antibody titers ≥1:5 the lower limit of the two-sided 95% confidence interval (CI) was ≥75%, directed against N.meningitidis serogroup B reference strains H44/76-SL , NZ98/254, 5/99, one month after the booster (fourth) dose of meningococcal B vaccine with or without the concomitant Measles, Mumps, Rubella, Varicella (MMRV) vaccine in toddlers who were previously vaccinated with three doses of Meningococcal B vaccine.
次要结局
- Number of Subjects Reporting Solicited Local and Systemic Reactions During the 7 Days Following Two-dose Catch-up Schedules of rMenB+OMV NZ Vaccination(From day 1 to day 7 after each rMenB+MV NZ vaccination.)
- Geometric Mean Titers After Receiving the Booster Dose and Single Dose of rMen+OMV NZ Vaccination (Induction of Immunological Memory)(one month after booster (fourth) dose vaccination and pre-fourth dose vaccination)
- SBA GMTs After a Two-dose Catch-up Schedule or Two-dose Schedule(One month after the second dose.)
- Percentages of Subjects With Antibody Response After Receiving the MMRV Vaccination(one month after booster (fourth) dose)
- ELISA Geometric Mean Concentration Against Vaccine Antigen 287-953 After Two-dose Catch-up in Toddlers(One month after the first dose and one month after the second dose.)
- Number of Subjects Reporting Solicited Local and Systemic Reactions During the 7 Days Following rMenB+OMV NZ Vaccination at 12 Months of Age(From day 1 to day 7 after each rMenB+OMV NZ vaccination.)
- Geometric Mean Titers at 12 Months of Age (Predose 4) After Previously Receiving the Three Doses of rMenB+OMV NZ (Persistence)(one month after third vaccination and pre dose fourth (booster) vaccination)
- Percentages of Subjects With Serum Bactericidal Antibody Titers ≥1:5 After Previously Receiving the Three Doses of rMenB+OMV NZ Vaccination (Persistence)(One month post vaccination and pe-booster (fourth) dose vaccination)
- Percentages of Subjects With SBA Titers ≥1:5 After a Two-dose Catch-up Schedule or Two-dose Schedule(One month after the second dose.)
- Number of Subjects Reporting Solicited Systemic Reactions During 8-28 Days Following MMRV Vaccination at 12 Months of Age(From day 8 to day 28 after MMRV vaccination.)
- The Geometric Mean Titers After Receiving the Booster Dose of rMenB+OMV NZ Vaccination(one month after booster (fourth) vaccination.)
- ELISA Geometric Mean Concentration Against Vaccine Antigen 287-953 One Month After the Fourth (Booster) Dose Given at 12 Months(One month after the fourth (booster) dose.)
- Percentages of Subjects With Bactericidal Titers ≥ 1:5 (95% CI) Against Strain M10713 One Month After the Fourth (Booster) Dose Given at 12 Months(One month after the fourth (booster) dose.)
- Number of Subjects Reporting Solicited Local Reactions During the 7 Days Following MMRV Vaccination at 12 Months of Age(From day 1 to day 7 after MMRV vaccination.)
研究者
研究点 (117)
Loading locations...
相似试验
已完成
3 期
An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia ASevere Hemophilia AHemophilia ANCT02172950CSL Behring246
已完成
2 期
Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered as Booster Dose at 12, 18 or 24 Months of Age in Toddlers (12-24 Months) Primed With a Three-Dose Immunization Series as Infants in Study V72P12Meningococcal DiseaseMeningococcal MeningitisNCT00944034Novartis Vaccines1,588
Enrolling By Invitation
3 期
Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C ReductionCardiovascular Disease With Mention of ArteriosclerosisElevated CholesterolFamilial HypercholesterolemiaNCT04798430LIB Therapeutics LLC2,000
进行中（未招募）
3 期
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)Non-Alcoholic Fatty Liver DiseaseNCT04951219Madrigal Pharmaceuticals, Inc.810
已完成
3 期
An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMDGeographic Atrophy Secondary to Age-related Macular DegenerationNCT04770545Apellis Pharmaceuticals, Inc.792